MYDECINE

News & Media

Mydecine Innovations’ Josh Bartch: The Last 12 Months Have Been Monumental For The Industry

March 4, 2021
Josh Bartch, Co-Founder & CEO of Mydecine, talks to Shadd Dales of The Dales Report to put recent company events in context.
Read More →

Mydecine Innovations Group cultivating low-cost psilocybin mushrooms at scale to treat PTSD

March 4, 2021
CEO Joshua Bartch tells Proactive the Colorado-based emerging biotech and life sciences company is making tremendous advancements.
Read More →

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain

March 1, 2021
Milestone means Mydecine is now able to access a quality source of product for research purposes and to sell and transfer to other licensed global research facilities.
Read More →

Mydecine Innovations: Unlocking Fungi’s Pharmacological and Nutraceutical Healing Properties

March 1, 2021
The Dales Report takes a look at Mydecine Innovations Group and its position in the world of early-stage psychedelic investing.
Read More →

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

February 24, 2021
Partnership Supports Mydecine’s Drug Development and Clinical Trials Pipeline; Provides Update on Debt Settlement.
Read More →

Behind the World-First Export of Jamaican Psilocybin Mushrooms

February 19, 2021
Mydecine’s Chief Scientific Officer and Co-Founder Rob Roscow talks first harvest and commercial export of legal psychedelic psilocybin mushrooms.
Read More →

Truffle Talk with Joshua Bartch of Mydecine Innovations Group

February 18, 2021
Co-founder and CEO Joshua Bartch speaks to Truffle Report about the company’s psychedelics research program.
Read More →

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technolog

February 17, 2021
Digital health platform will combine telemedicine, on-demand mental health programs and advanced wellbeing analytics.
Read More →

Mydecine Innovations Group Partners with Microdose to Present a Webinar on Psychedelic Drug Development

February 16, 2021
Mydecine panelists will discuss if Psychedelic Drug Design can Improve Safety and Efficacy for Medicine.
Read More →

Magic mushroom therapy could help treat PTSD in Canadian military vets

February 16, 2021
Mydecine's Chief Medical Officer offers a few hypotheses as to why PTSD in veterans can be difficult to treat.
Read More →

Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

February 12, 2021
Offering further strengthens Mydecine’s balance sheet and positions the Company for continued growth in 2021.
Read More →

The Current Status of Psychedelics in Psychiatry

February 4, 2021
Mydecine Innovations Group Advisory Board Member Robin Carhart-Harris, PhD and David Nutt, MD, PhD provide viewpoint on industry progress.
Read More →

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors

February 3, 2021
Wu brings in an extensive network of experts in operation, clinical, market positioning and regulatory knowledge in the Pan Asia healthcare landscape.
Read More →

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange

February 1, 2021
With the move, the company is positioning its common shares to be traded on a senior exchange in Canada, providing exposure to more investors.
Read More →

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

January 28, 2021
The research goal is to get a better understanding of when, where and how psilocybin is most appropriate for use in human therapeutics.
Read More →

Mydecine Innovations Group Files Application to list to the NASDAQ

January 27, 2021
Mydecine submitted a formal application to list its common shares on the second largest exchange by market capitalization worldwide.
Read More →

Research and Development Moves the Psychedelics Market Forward

January 27, 2021
FN Media Group presents Microsmallcap.com market commentary on the companies that are commercializing psychedelic medicines.
Read More →

Microdosing Mysteries: The New Science Exploring Tiny Doses of Psychedelics

January 24, 2021
New Atlas's Flipboard aggregates some of the top stories from around the world on the subject of psychedelics.
Read More →

Mydecine Innovations Group Included in First-Ever Psychedelics ETF

January 22, 2021
Mydecine is one of 17 companies to be included in the Horizons Psychedelic Stock Index Exchanged Traded Fund (ETF).
Read More →

Mydecine Innovations Group Files Preliminary Prospectus

January 21, 2021
Prospectus filing is in connection with its bought deal offering previously announced on January 14, 2021.
Read More →

Mydecine Co-founder and CEO sees a big future for psilocybin and other mushroom-based compounds

January 17, 2021
Josh Bartch highlights how Mydecine Innovations Group is well positioned in the pharmaceuticals and consumer packaged goods industries.
Read More →

Researchers will soon test psychosubstances as a potential treatment for veterans with PTSD.

January 14, 2021
Mydecine's Rakesh Jetly, MD joins HCPLive® to talk about how research is on the cutting edge of a breakthrough treating trauma.
Read More →

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

January 14, 2021
The emerging biopharma and life sciences company announces that it has entered into an agreement with Canaccord Genuity Corp.
Read More →

Mydecine Innovations Group Upsizes Previously Announced Bought Deal

January 14, 2021
Mydecine announces that it has agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity Corp.
Read More →

Mydecine Innovations Group Uniquely Positioned To Take Over 2021

January 13, 2021
Microdose Psychedelic Insights, which provides Psychedelic industry insight and market intelligence, believes the future is bright for Mydecine.
Read More →

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer

January 11, 2021
MYCO Continues to Strengthen Board of Directors in Anticipation of Senior Exchange Listing Requirements.
Read More →

As the Focus on Psychedelic Stocks Increases, So Do the Valuations

January 11, 2021
The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
Read More →

5 Groovy Psychedelic Stocks to Buy

January 8, 2021
Investor Place reports that “The Times They Are A-Changin’” for psychedelic mental health treatments.
Read More →

Mydecine Innovations Group Shares Intellectual Property Update

January 7, 2021
Mydecine Innovations Group files seven provisional patent applications with United States Patent and Trademark Office.
Read More →

Further Research into Psilocybin Opens New Doors for Treatment

January 7, 2021
Financial Buzz highlights five companies, including Mydecine Innovations Group, that are leading research efforts into Psilocybin.
Read More →

2020 Was A Year of Historic Firsts That Set the Stage for the Psychedelic Renaissance

January 6, 2021
Microdose Psychedelic Insights breaks down all the psychedelic industry advancements made in the year 2020.
Read More →

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

January 5, 2021
Study will also be the first to use Magnetoencephalography, or MEG scans, to identify brain activity, along with planned cognitive and biometric measures, while microdosing.
Read More →

The Year In Review For Psychedelic Drug Stocks: 2020

December 23, 2020
Multi-bagger returns for several companies; Large and rising capital flows into the industry; Very favorable media coverage and public opinion.
Read More →

Psychedelic Scientist Robin Carhart Harris Leads The Research Renaissance With Over 100 Peer-Reviewed Publications

December 23, 2020
Highlighting notable scientific achievements Harris has made towards advancing the psychedelic renaissance.
Read More →

Psychedelics Industry Gearing Up For an Even Bigger 2021

December 21, 2020
Mydecine Innovations Group is focused on developing and commercializing innovative solutions to treat mental health problems and enhance well being.
Read More →

Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials

December 21, 2020
Mydecine has engaged ethica CRO, a full-service Contract Research Organization (“CRO”) that conducts and manages ethical clinical research.
Read More →

Mydecine Speaker Series: Psychedelic Solutions

December 21, 2020
Mydecine panellists discuss psychedelic solutions in speaker series moderated by Business Insider journalist Yeji Lee.
Read More →

2020: A Year In Review for the Psychedelic Renaissance

December 20, 2020
The year 2020 has been a really big year for magic mushrooms and the fast-paced growth of psychedelic medicine.
Read More →

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

December 15, 2020
Leading FDA consultancy firm ProPharma Group to advise on drug development and clinical trial pipeline.
Read More →

Push for Alternative Therapies Prods Researchers Towards Psilocybin

December 15, 2020
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends, provides update on Mydecine.
Read More →

Mydecine to make first legal import of psilocybin mushrooms into Canada

December 11, 2020
Canada continues to open the door for clinical research the effectiveness of psilocybin for mental health treatments.
Read More →

Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics

December 10, 2020
Panelists will discuss the impact of cutting edge research in mainstream medical interest about unlocking the potential of psychedelic therapies.
Read More →

Top Mushroom Penny Stocks To Watch For 2021

December 10, 2020
Are you Looking For Top Mushroom Stocks Right Now? Psychedelic Stocks To Watch Heading Into The New Year.
Read More →

Psychedelics: FDI’s next trip?

December 9, 2020
Psilocybin-based therapies are gaining ground in the US, sparking investment in the sector with a recent rush of investor interest.
Read More →

Psychedelic Quick Hits: Havn Life, MindMed, Mydecine

December 9, 2020
The cannabis industry's leading financial news source highlights Mydecine's first commercial harvest of natural psilocybin mushrooms.
Read More →

Spotlight: Dr. Denton Hoyer, Scientific Advisor, Mydecine

December 9, 2020
Hoyer shares his insight into psychedelic derived medicines, his experience with large Pharma companies, and what he's working on at Mydecine.
Read More →

Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

December 8, 2020
Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybin.
Read More →

Health Crisis-Induced Post-Traumatic Stress Disorder Creates Growing Need for Treatment Options

December 8, 2020
FN (Financial News) Media Group Presents Microsmallcap.com Market Commentary with Updates on Mydecine Innovations Group.
Read More →

Plant Medicine Expands into New Realms

December 8, 2020
Webcast: From Cannabis to Mycology, Damon Michaels of Mydecine talks about his transition with Genifer Murray on Inside the Industry.
Read More →

Understanding The Psilocybin Supply Chain: Every Production Method Explained

December 2, 2020
As psychedelics-assisted therapy gains momentum, investors need to understand the difference between the current available means of obtaining psilocybin.
Read More →

Q&A Spotlight: Dr. Rakesh Jetly, Chief Medical Officer, Mydecine

November 30, 2020
Jetly discusses his background and viewpoints on a variety of topics in the world of psychedelics and the treatment of PTSD in soldiers.
Read More →

Clinical trial explores psychedelic treatments for PTSD in veterans

November 25, 2020
A company exploring the efficacy of psychedelic treatments for PTSD in veterans has announced the international expansion of its Phase 2A clinical trials.
Read More →

Psychedelics Transition from Experimental Treatment to Major Pharmaceutical Industry

November 20, 2020
Mydecine Innovations Group Inc. is an emerging biopharma and life sciences company that is committed to the research, development and acceptance of alternative nature-sourced medicine.
Read More →

Is Compass Pathways Stock a Buy?

November 18, 2020
Oregon just decriminalized the use of the psychedelic compound psilocybin. Could Compass Pathways, which is testing a synthetic form of the drug as a mental health therapy, be on the cusp of something big?
Read More →

Mydecine Innovations Group Offers Management and Clinical Trials Update

November 17, 2020
Company Announces International Expansion of Clinical Trial Sites for Phase 2A Study into Psychedelic Treatments for PTSD in Veterans.
Read More →

More U.S. Military Funding For Psychedelic Drug R&D As PTSD Crisis Worsens

November 16, 2020
From crisis comes opportunity. The worsening PTSD crisis among military personnel (and first responders) may be the quickest path to legalization for a new psychedelic medicine.
Read More →

MYCO Times: Newsletter (November)

November 9, 2020
Get the latest news from Mydecine Innovations Group, Inc. including a note from Chairman and CEO Joshua Bartch.
Read More →

Magic Mushroom Compound Called Psilocybin May Help Treat Depression

November 7, 2020
New study says psychedelic substance found in magic mushrooms can relieve symptoms in people with major depressive disorder.
Read More →

Mydecine Innovations Group Retains KCSA Strategic Communications

November 6, 2020
The fully integrated communications agency to provide public relations and social media counsel for the emerging biopharma and life sciences company.
Read More →

Q&A Spotlight: Robert Roscow, CSO at Mydecine Innovations Group

November 3, 2020
Roscow has set his focus on the vast healing potential of the safe and effective compounds found in fungi.
Read More →

Exploring Non-Dilutive Grant Funding for Clinical Trial Initiatives: Q&A with Mydecine CEO Josh Bartch

October 22, 2020
Mydecine's CEO Josh Bartch talks therapeutic medicine funding and market listings with the editor-in-chief of IPO-Edge.
Read More →

Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

October 16, 2020
A listing on the LSE makes it well-positioned to bring European investors into the Company’s share register.
Read More →

NeuroPharm Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities

October 14, 2020
A wide range of government and private non-dilutive funding sources are available for the disorders being addressed by NeuroPharm.
Read More →

Numinus (CSE:NUMI) or Mydecine (CSE:MYCO)? Two Psychedelics Investing Options

October 14, 2020
‍The two industry leaders among psychedelic stocks have already carved out their own followings among psychedelic stock investors.
Read More →

Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores

September 30, 2020
Mindleap's digital telehealth mobile application for mental coaching and wellbeing is now available for download.
Read More →

Mindleap Launches Digital Platform Intended For Psychedelic Aftercare

September 24, 2020
Green Market Report reports Mindleap Health has launched a digital health platform that combines telehealth with mood, emotion, and habit tracking.
Read More →

New App, Mindleap, Aims To Revolutionize Psychedelic Use And Wellness

September 24, 2020
High Times article details a new Mindleap app that connects mental health professionals with people using psychedelics.
Read More →

Psychedelics Companies Look To 'Functional Mushrooms' For Opportunities

September 21, 2020
In recent years mushrooms left their dark, hidden habitats to jump into the spotlight of consumer markets.
Read More →

Mydecine Innovations Group Would Like to Give Thanks to its Shareholders for Extending the Lockup on the Five Cent Placement for Another 120 Days

September 3, 2020
MIG shareholders have agreed to extend lock-up restrictions that were due to be released on September 6, 2020, for an additional 120 days.
Read More →

Mydecine Innovations Group Completes Acquisition of NeuroPharm Inc.

September 3, 2020
Mydecine Innovations Group Inc. has closed its previously announced acquisition of NeuroPharm Inc., a developer of natural health, psychedelic-based treatments for post-traumatic stress disorder and other serious mental health disorders.
Read More →

The Trip Report: Psilocybin Cultivation and Delivery Trends

August 24, 2020
Industry newsletter The Trip Report highlighted Mydecine as one of the few companies planning to produce psilocybin from natural products.
Read More →

Mydecine gets first CGMP status to produce, sell and export medical psilocybin

August 21, 2020
The Denver-based company says the new milestone will advance global research for medical psilocybin as depression rises during the pandemic.
Read More →

Will Mydecine's Move Make the Market for Pharmaceutical Psilocybin Mushroom?

August 21, 2020
Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.
Read More →

Mydecine Innovations Group Adds Dr. Robin Carhart-Harris and Dr. David Erritzoe to Scientific Advisory Board

August 19, 2020
Mydecine Innovations Group Inc. announces two new strategic advisors to the company's Scientific Advisory Board.
Read More →

Mydecine™ Launches World's First Natural-Sourced cGMP Psilocybin for Global Research, Sales, and Distribution Enterprise

August 18, 2020
Mydecine™ becomes first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade, naturally derived psilocybin.
Read More →

Mydecine Innovations Group Featured in Forbes for the First-Of-Its-Kind Clinicals Using Psilocybin Therapy For PTSD

August 13, 2020
NeuroPharm Inc. was recently covered in Forbes for its ground-breaking psilocybin clinical trials for treatment of posttraumatic stress disorder (PTSD)
Read More →

Mydecine Innovations Group Provides Inaugural Corporate Update in the Expanding Psychedelic Medicines Sector

August 12, 2020
Mydecine Innovations Group Inc. is pleased to provide a corporate update regarding recent advancements and achievements that continues to add shareholder value
Read More →

First-Of-Its-Kind Clinical Trial To Study Psychedelic Treatments For PTSD In Veterans

August 12, 2020
Psychedelics-based treatments developer NeuroPharm Inc. recently announced it would be collaborating on clinical trials for the treatment of posttraumatic stress disorder (PTSD)
Read More →

Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness

August 4, 2020
Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness
Read More →

Ex-Canopy Growth Geneticist Turns His Focus to Psychedelics

July 29, 2020
Recently it was announced that ebbu's Director of Research, Robert Roscow, M.A., would leave a cannabis industry conglomerate to become the Chief Science Officer of the leading psychedelic startup ...
Read More →

Mydecine Innovations Group Inc. Appoints Previous Red Bull Sports Marketing Director Jim Gunning as CMO

July 24, 2020
Mydecine Innovations Group Inc. is pleased to announce that they have hired former Red Bull marketing executive, Jim Gunning, as the Company’s new Chief Marketing Officer (“CMO”).
Read More →

Mushroom company Mydecine acquires veteran-focused psychedelic firm

July 15, 2020
Denver-based Mydecine Innovations Group Inc. continues to expand its fungi footprint deeper into North America.
Read More →

Psychedelic Compounds Could be Used in Mental Healthcare

July 15, 2020
There is a need for new antidepressants with a mechanism of action different from that of SSRIs and SNRIs to improve efficacy across several symptoms
Read More →

Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc.

July 14, 2020
Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc. Positioned as a Leader in the Development of Psychedelic Treatments for the Betterment of Veterans
Read More →

Mydecine Innovations Group Adds World Renowned, 7-Time Nobel Peace Prize Nominee Dr. M.S Reddy to its Scientific Advisory Board

July 7, 2020
Mydecine Innovations Group Inc. announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor.
Read More →

Mydecine Adds 7-Time Nobel Prize Nominee Dr. M.S Reddy to its Scientific Advisory Board

July 7, 2020
Mydecine Innovations Group Inc. announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor.
Read More →

Mydecine Innovations Group Adds World Renowned, 7-time Nobel Peace Prize Nominee Dr. M.s Reddy to Its Scientific Advisory Board

July 7, 2020
Mydecine Innovations Group Inc. announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor.
Read More →

Psychedelics Represent a New Frontier for Mental Healthcare

July 7, 2020
NEW YORK: Despite the various stigmas associated with psychedelics, there is a growing acceptance of using psychedelic drugs specifically to treat depression.
Read More →

Regulators Move to Remove Restriction on Some Uses of Psilocybin

July 6, 2020
NEW YORK, July 6, 2020 /PRNewswire/ -- The political push for the legalization of psychedelic products is now underway.
Read More →

Positive First Steps Show the Promise of Psychedelic Therapies

July 4, 2020
NEW YORK: Depression and PTSD are serious psychiatric disorders which happen to share some similar symptoms. Either disorder might cause trouble sleeping, anger over little things, or a loss of interest in people or things.
Read More →

Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board

June 30, 2020
Mydecine Innovations Group Inc. is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board.
Read More →

Mydecine Innovations Group Inc. has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board.

June 30, 2020
Mydecine Innovations Group Inc. is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board.
Read More →

Psychedelic Medicine Stocks Garner Serious Investor Interest

June 25, 2020
So much interest in psychedelics medicine that some analysts see the industry bringing in $6.85 billion by 2027 .
Read More →

Research Uncovers New Role Psychedelics Could Play in Therapy

June 25, 2020
The pharmaceutical industry develops drugs to diagnose, cure, treat or prevent diseases and it operates in one of the most diverse and complex markets.
Read More →

Researchers Delve Into Psychedelics in Search of Novel Therapies

June 24, 2020
NEW YORK: The trend of cannabis legalization in several countries is one of the key factors driving the market's growth.
Read More →

Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist

June 23, 2020
Mydecine Innovations Group Inc. is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee.
Read More →

Mydecine Innovations Group Bolsters Scientific Advisory Board

June 23, 2020
Mydecine Innovations Group Inc.(OTC: MYCOF) (CSE: MYCO), is pleased to announce the addition of two key strategic advisors to the company’s Scientific Advisory Committee.
Read More →

“Buzz on the Street” Show: Mydecine Innovations Group (OTC: MYCOF) (CSE: MYCO) Scientific Advisory

June 23, 2020
Featuring Our Corporate News Recap on “Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist.”
Read More →

Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist

June 23, 2020
Mydecine Innovations Group Inc. is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee.
Read More →

'Psyched': Mydecine Launches New Research Partnership

June 22, 2020
Oregon-founded psychedelics company Silo Wellness announced June 17 the singing of a binding letter of intent to combine its business operations with Yukoterre Resources Inc.
Read More →
← Back to homepage